Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) Gross Profit (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Gross Profit for 17 consecutive years, with $220.9 million as the latest value for Q4 2025.

  • Quarterly Gross Profit fell 11.32% to $220.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $831.6 million through Dec 2025, down 5.72% year-over-year, with the annual reading at $831.6 million for FY2025, 5.72% down from the prior year.
  • Gross Profit hit $220.9 million in Q4 2025 for Integra Lifesciences Holdings, up from $207.0 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $250.1 million in Q4 2022 to a low of $194.4 million in Q1 2025.
  • Historically, Gross Profit has averaged $225.7 million across 5 years, with a median of $226.2 million in 2023.
  • Biggest five-year swings in Gross Profit: soared 55.84% in 2021 and later decreased 16.99% in 2023.
  • Year by year, Gross Profit stood at $249.3 million in 2021, then grew by 0.33% to $250.1 million in 2022, then fell by 9.43% to $226.5 million in 2023, then increased by 9.97% to $249.1 million in 2024, then fell by 11.32% to $220.9 million in 2025.
  • Business Quant data shows Gross Profit for IART at $220.9 million in Q4 2025, $207.0 million in Q3 2025, and $209.3 million in Q2 2025.